- Evolus (EOLS) Q2 results: Revenues: $2.3M.
- Net loss: ($37.6M) (-129.3%); loss/share: ($1.37) (-98.6%); Quick Assets: $99.9M (+7.2%).
- The Company launched NEWTOX NOW $75 consumer coupon program on July 1, designed to accelerate Jeuveau conversion.
- Evolus received a revised positive CHMP opinion for Nuceiva (prabotulinumtoxinA-xvfs) (branded as Jeuveau in U.S.) and now expect European approval in H2.
- Shares are up 2% premarket.
- Previously: Evolus EPS misses by $0.25, beats on revenue (Aug. 12)